VTRS Quote, Financials, Valuation and Earnings

Amphastar Pharmaceuticals has a net margin of -14.64% compared to Viatris's net margin of 20.35%. Viatris's return on equity of -3.22% beat Amphastar Pharmaceuticals's return on equity of 22.89%.

Viatris has a consensus price target of $11.7625, signalling upside risk potential of 24.87%. On the other hand Amphastar Pharmaceuticals has an analysts' consensus of $39.00 which suggests that it could grow by 39.99%. Given that Amphastar Pharmaceuticals has higher upside potential than Viatris, analysts believe Amphastar Pharmaceuticals is more attractive than Viatris.

Viatris has a beta of 0.922, which suggesting that the stock is 7.819% less volatile than S&P 500. In comparison Amphastar Pharmaceuticals has a beta of 0.768, suggesting its less volatile than the S&P 500 by 23.238%.

Viatris has a quarterly dividend of $0.12 per share corresponding to a yield of 5.1%. Amphastar Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Viatris pays -90.63% of its earnings as a dividend. Amphastar Pharmaceuticals pays out -- of its earnings as a dividend.

Viatris quarterly revenues are $3.5B, which are larger than Amphastar Pharmaceuticals quarterly revenues of $186.5M. Viatris's net income of -$516.5M is lower than Amphastar Pharmaceuticals's net income of $38M. Notably, Viatris's price-to-earnings ratio is -- while Amphastar Pharmaceuticals's PE ratio is 9.10x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Viatris is 0.77x versus 1.98x for Amphastar Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

ANI Pharmaceuticals has a net margin of -14.64% compared to Viatris's net margin of -5.39%. Viatris's return on equity of -3.22% beat ANI Pharmaceuticals's return on equity of -4.07%.

Viatris has a consensus price target of $11.7625, signalling upside risk potential of 24.87%. On the other hand ANI Pharmaceuticals has an analysts' consensus of $81.50 which suggests that it could grow by 25.64%. Given that ANI Pharmaceuticals has higher upside potential than Viatris, analysts believe ANI Pharmaceuticals is more attractive than Viatris.

Viatris has a beta of 0.922, which suggesting that the stock is 7.819% less volatile than S&P 500. In comparison ANI Pharmaceuticals has a beta of 0.625, suggesting its less volatile than the S&P 500 by 37.453%.

Viatris has a quarterly dividend of $0.12 per share corresponding to a yield of 5.1%. ANI Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Viatris pays -90.63% of its earnings as a dividend. ANI Pharmaceuticals pays out -8.77% of its earnings as a dividend.

Viatris quarterly revenues are $3.5B, which are larger than ANI Pharmaceuticals quarterly revenues of $190.6M. Viatris's net income of -$516.5M is lower than ANI Pharmaceuticals's net income of -$10.3M. Notably, Viatris's price-to-earnings ratio is -- while ANI Pharmaceuticals's PE ratio is 55.43x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Viatris is 0.77x versus 2.05x for ANI Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Merck & has a net margin of -14.64% compared to Viatris's net margin of 23.96%. Viatris's return on equity of -3.22% beat Merck &'s return on equity of 40.25%.

Viatris has a consensus price target of $11.7625, signalling upside risk potential of 24.87%. On the other hand Merck & has an analysts' consensus of $112.29 which suggests that it could grow by 19.43%. Given that Viatris has higher upside potential than Merck &, analysts believe Viatris is more attractive than Merck &.

Viatris has a beta of 0.922, which suggesting that the stock is 7.819% less volatile than S&P 500. In comparison Merck & has a beta of 0.348, suggesting its less volatile than the S&P 500 by 65.24%.

Viatris has a quarterly dividend of $0.12 per share corresponding to a yield of 5.1%. Merck & offers a yield of 3.36% to investors and pays a quarterly dividend of $0.81 per share. Viatris pays -90.63% of its earnings as a dividend. Merck & pays out 45.8% of its earnings as a dividend. Merck &'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Viatris quarterly revenues are $3.5B, which are smaller than Merck & quarterly revenues of $15.6B. Viatris's net income of -$516.5M is lower than Merck &'s net income of $3.7B. Notably, Viatris's price-to-earnings ratio is -- while Merck &'s PE ratio is 13.97x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Viatris is 0.77x versus 3.72x for Merck &. Usually stocks with elevated PS ratios are considered overvalued.

Teleflex has a net margin of -14.64% compared to Viatris's net margin of -17.18%. Viatris's return on equity of -3.22% beat Teleflex's return on equity of 1.57%.

Viatris has a consensus price target of $11.7625, signalling upside risk potential of 24.87%. On the other hand Teleflex has an analysts' consensus of $168.21 which suggests that it could grow by 20.82%. Given that Viatris has higher upside potential than Teleflex, analysts believe Viatris is more attractive than Teleflex.

Viatris has a beta of 0.922, which suggesting that the stock is 7.819% less volatile than S&P 500. In comparison Teleflex has a beta of 1.211, suggesting its more volatile than the S&P 500 by 21.134%.

Viatris has a quarterly dividend of $0.12 per share corresponding to a yield of 5.1%. Teleflex offers a yield of 0.98% to investors and pays a quarterly dividend of $0.34 per share. Viatris pays -90.63% of its earnings as a dividend. Teleflex pays out 91.2% of its earnings as a dividend. Teleflex's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Viatris quarterly revenues are $3.5B, which are larger than Teleflex quarterly revenues of $795.4M. Viatris's net income of -$516.5M is lower than Teleflex's net income of -$136.7M. Notably, Viatris's price-to-earnings ratio is -- while Teleflex's PE ratio is 98.05x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Viatris is 0.77x versus 2.15x for Teleflex. Usually stocks with elevated PS ratios are considered overvalued.